Francesco Passamonti

Q: What Schools Are Affiliated With Francesco Passamonti

Francesco Passamonti is affiliated with the following schools: University of Insubria, University of Milan, University of Pavia, University of Padua, University of Barcelona, University of Bologna

Francesco Passamonti's AcademicInfluence.com Rankings

Physics

#6382

World Rank

#8322

Historical Rank

physics Degrees

Download Badge

Physics

Francesco Passamonti's Degrees

PhD Physics University of Milan
Masters Physics University of Milan
Bachelors Physics University of Milan

Why Is Francesco Passamonti Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Francesco Passamonti's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A gain-of-function mutation of JAK2 in myeloproliferative disorders. (2005) (3438)
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. (2008) (1098)
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. (2011) (833)
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. (2005) (827)
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). (2010) (798)
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. (2011) (745)
Ruxolitinib versus standard therapy for the treatment of polycythemia vera. (2015) (587)
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study (2013) (506)
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons (2014) (477)
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment (2008) (456)
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. (2004) (441)
Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). (2012) (424)
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. (2011) (415)
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. (2013) (381)
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. (2011) (365)
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet (2018) (342)
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study (2020) (339)
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications (2010) (334)
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. (2012) (328)
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. (2015) (310)
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. (2008) (302)
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. (2011) (290)
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. (2017) (287)
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. (2006) (280)
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. (2013) (269)
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients (2008) (251)
International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. (2022) (249)
A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. (2012) (227)
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. (2009) (227)
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. (2011) (213)
Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group (2015) (211)
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis (2017) (205)
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. (2013) (200)
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. (2009) (200)
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. (2012) (199)
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. (2017) (198)
Pomalidomide is active in the treatment of anemia associated with myelofibrosis. (2009) (198)
Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders (2008) (192)
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. (2005) (187)
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. (2017) (187)
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients (2014) (184)
Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia (2015) (165)
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. (2011) (164)
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea (2013) (164)
Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. (2010) (157)
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. (2018) (155)
Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. (2007) (153)
Deletions of the transcription factor Ikaros in myeloproliferative neoplasms (2010) (146)
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial (2016) (144)
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. (2009) (143)
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process (2010) (143)
Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. (2015) (139)
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria (2012) (139)
Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles (2004) (135)
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. (2007) (134)
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations (2011) (127)
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA) (2021) (126)
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. (2007) (126)
How I treat polycythemia vera. (2012) (122)
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. (2017) (121)
Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. (2006) (113)
Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. (2003) (112)
Hydroxyurea‐related toxicity in 3,411 patients with Ph'‐negative MPN (2012) (109)
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. (2022) (109)
Improving survival trends in primary myelofibrosis: an international study. (2012) (106)
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. (2014) (103)
Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine. (1999) (96)
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. (2013) (95)
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. (2014) (94)
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders (2006) (94)
Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts (2018) (92)
Muco‐cutaneous changes during long‐term therapy with hydroxyurea in chronic myeloid leukaemia (2001) (92)
Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. (2012) (89)
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma (2010) (88)
Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia (2009) (86)
Clinical relevance of JAK2 (V617F) mutant allele burden (2009) (81)
Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients. (2000) (79)
Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. (2014) (76)
Primary nodal marginal zone B‐cell lymphoma: clinical features and prognostic assessment of a rare disease (2007) (74)
Long-term Events in Adult Patients with Clinical Stage IA-IIA Nonbulky Hodgkin's Lymphoma Treated with Four Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Adjuvant Radiotherapy: A Single-Institution 15-Year Follow-up (2006) (73)
Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy (2013) (72)
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure (2020) (72)
The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double‐blind, double‐dummy, symptom study (RELIEF) (2014) (72)
Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients. (2009) (72)
Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. (2014) (72)
What are RBC-transfusion-dependence and -independence? (2011) (72)
The ‘GGCC’ haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera (2009) (70)
Leukemic transformation of polycythemia vera (2005) (69)
Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group (2016) (69)
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms (2011) (69)
Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients (2011) (68)
Transfusion‐dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis—prognostic relevance is independent of IPSS or karyotype (2009) (67)
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes (2021) (66)
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations (2007) (65)
Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity. (2000) (64)
Durable Responses with the JAK1/ JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU) (2010) (64)
The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms (2011) (64)
Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. (2012) (64)
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. (2020) (63)
Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination. (2006) (62)
Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project (2014) (61)
Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia. (2013) (59)
Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF) (2012) (58)
Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of 3 cases. (2005) (57)
Impact of treatment‐related liver toxicity on the outcome of HCV‐positive non‐Hodgkin's lymphomas (2009) (56)
Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. (2003) (55)
A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence (2016) (54)
Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies (2011) (52)
Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS (2011) (52)
Leukocytosis as an important risk factor for arterial thrombosis in WHO‐defined early/prefibrotic myelofibrosis: An international study of 264 patients (2012) (51)
Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. (2010) (51)
Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. (2016) (51)
A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea. (2009) (51)
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients (2015) (49)
Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. (2017) (48)
Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases. (2014) (48)
A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia (2019) (48)
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas. (2018) (48)
Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. (2013) (47)
Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial (2018) (47)
Changes in quality of life and disease‐related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy (2016) (46)
Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history (2015) (45)
COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA (2021) (45)
Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients. (2001) (45)
COVID‐19 elicits an impaired antibody response against SARS‐CoV‐2 in patients with haematological malignancies (2021) (45)
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub (2018) (44)
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) (2014) (43)
Germline RBBP6 mutations in familial myeloproliferative neoplasms. (2016) (43)
Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group (2016) (43)
Update from the latest WHO classification of MPNs: a user's manual. (2016) (42)
Splenic marginal zone lymphoma: Clinical clustering of immunoglobulin heavy chain repertoires. (2009) (41)
JAK inhibitor in CALR-mutant myelofibrosis. (2014) (41)
Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. (2008) (41)
The role of JAK2 inhibitors in MPNs 7 years after approval. (2018) (40)
Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations (2017) (40)
Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients (2010) (39)
Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis (2002) (39)
Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea (2002) (39)
Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patients (Pts) with Myelofibrosis (MF) (2015) (39)
Clinical significance of neutrophil CD177 mRNA expression in Ph‐negative chronic myeloproliferative disorders (2004) (39)
Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies (2010) (37)
Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis (2021) (37)
Identification of genomic aberrations associated with disease transformation by means of high‐resolution SNP array analysis in patients with myeloproliferative neoplasm (2011) (37)
Increase in leukocyte count over time predicts thrombosis in patients with low‐risk essential thrombocythemia (2009) (36)
Leukemia risk models in primary myelofibrosis: an International Working Group study (2012) (36)
JAK2 (V617F) mutation in healthy individuals (2007) (36)
Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients (2017) (36)
Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations (2009) (34)
Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma. (2004) (34)
Dyspnea secondary to pulmonary hematopoiesis as presenting symptom of myelofibrosis with myeloid metaplasia (2006) (34)
correspondence: Incidence of leukaemia in patients with primary myelofibrosis and RBC–transfusion‐dependence (2010) (32)
A novel germline JAK2 mutation in familial myeloproliferative neoplasms (2014) (32)
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman (2004) (31)
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V 617 F mutation of Jak 2 (2005) (31)
Causes of equine abortion, stillbirth and neonatal death in central Italy (2012) (29)
Results Of a Randomized, Double-Blind, Placebo-Controlled Phase III Study (JAKARTA) Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF) (2013) (29)
Reductions in JAK2 V617F Allele Burden with Ruxolitinib Treatment in Comfort-II, a Phase 3 Study Comparing the Safety and Efficacy of Ruxolitinib with Best Available Therapy (BAT) (2012) (28)
Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence (2013) (28)
Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper. (2014) (27)
New generation small-molecule inhibitors in myeloproliferative neoplasms (2012) (27)
Assessment of bone marrow involvement in non‐Hodgkin’s lymphomas: comparison between histology and flow cytometry (2010) (27)
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis (2009) (26)
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project (2018) (25)
A long‐term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients (2007) (25)
Looking for CALR mutations in familial myeloproliferative neoplasms (2014) (25)
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study (2021) (25)
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia (2012) (24)
Ruxolitinib Provides Reductions in Splenomegaly Across Subgroups: An Analysis of Spleen Response in the COMFORT-II Study (2011) (24)
Comparison of Outcomes of Advanced Myelofibrosis Patients Treated with Ruxolitinib (INCB018424) to Those of a Historical Control Group: Survival Advantage of Ruxolitinib Therapy (2011) (24)
A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF): Identification Of The Recommended Phase 2 Dose (2013) (23)
Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies (2018) (23)
Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera (2018) (22)
Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma. (2021) (22)
New molecular genetics in the diagnosis and treatment of myeloproliferative neoplasms (2016) (22)
Efficacy and safety of an infectious bursal disease virus intermediate vaccine in ovo. (2001) (22)
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. (2022) (21)
A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis (2018) (21)
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis (2022) (20)
Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) - Updated Data from the Phase 2 ACE-536-MF-001 Study (2020) (20)
Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment. (2006) (20)
An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis: Results from HARMONY Study (2015) (20)
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study (2021) (19)
High-resolution genome-wide array comparative genomic hybridization in splenic marginal zone B-cell lymphoma. (2009) (19)
Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses. (2020) (19)
Survival and Risk of Leukemic transformation in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study on 1,104 Patients (2010) (19)
European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012;97(3):360–5 - Comment (2012) (19)
Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial (2014) (19)
It is time to change thrombosis risk assessment for PV and ET? (2014) (19)
Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia. (2014) (19)
Long-Term Efficacy and Safety Results From a Phase II Study of Ruxolitinib in Patients with Polycythemia Vera (2012) (19)
Long-term Results From a Phase II Open-label Study of Ruxolitinib in Patients With Essential Thrombocythemia Refractory to or Intolerant of Hydroxyurea (2014) (18)
Exaggerated insect bite-like reaction in patients affected by oncohaematological diseases. (2005) (18)
Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients (2017) (18)
DYNAMO: a PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE‐REFRACTORY INDOLENT NON‐HODGKIN LYMPHOMA (2017) (18)
Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO‐criteria and stratified by calendar period of diagnosis (2015) (18)
EPICOVIDEHA: A Ready to Use Platform for Epidemiological Studies in Hematological Patients With COVID-19 (2021) (18)
COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP (2021) (18)
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study (2021) (18)
Leukemia Risk Models in Primary Myelofibrosis: An International Working Group Study, (2011) (18)
Recurrence of immune thrombocytopenia at the time of SARS-CoV-2 infection (2020) (18)
Efficacy and Safety Of Fedratinib (SAR302503/TG101348) In Patients With Intermediate- Or High-Risk Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Or Post-Essential Thrombocythemia (ET) MF Previously Treated With Ruxolitinib: Interim Results From a Phase II Study (JAKARTA-2) (2013) (17)
Phase 3 randomized trial of momelotinib (MMB) versus best available therapy (BAT) in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX). (2017) (17)
The Relationship Between Cytokine Levels and Symptoms in Patients (Pts) With Myelofibrosis (MF) From COMFORT-II, a Phase 3 Study of Ruxolitinib (RUX) Vs Best Available Therapy (BAT) (2013) (17)
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus (2022) (17)
Everolimus in diffuse large B-cell lymphomas. (2015) (17)
Survival and Prognosis Among 1,263 Patients with Polycythemia Vera: An International Study (2011) (17)
Insertion sequence IS256 in canine pyoderma isolates of Staphylococcus pseudintermedius associated with antibiotic resistance. (2012) (17)
Disease anticipation in familial myeloproliferative neoplasms. (2008) (16)
Clinical relevance of clonal hematopoiesis in the oldest-old population. (2021) (16)
The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group (2016) (16)
Treatment of Polycythemia Vera and Essential Thrombocythemia: The Role of Pipobroman (2003) (15)
Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-Naïve or were Previously Treated with Ruxolitinib (2019) (15)
Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study. (2019) (15)
Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis (2018) (15)
COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey (2020) (15)
Survival in young patients with intermediate‐/high‐risk myelofibrosis: Estimates derived from databases for non transplant patients (2009) (15)
How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy—a GIMEMA MPN WP survey (2020) (15)
Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. (2017) (14)
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey (2022) (14)
Three-year ef ﬁ cacy, safety, and survival ﬁ ndings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelo ﬁ brosis (2013) (14)
Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk Myelofibrosis (2014) (14)
Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders. (2006) (14)
Myeloproliferative (MPN) Symptom Burden Response Thresholds: Assessment Of MPN-SAF TSS Quartiles As Potential Markers Of Symptom Response (2013) (13)
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients (2019) (13)
Stem cell transplant in MF: it's time to personalize. (2019) (13)
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project (2018) (13)
Novel agents in indolent lymphomas (2013) (13)
Ruxolitinib and survival improvement in patients with myelofibrosis (2014) (13)
Germline RBBP6 Mutations In Myeloproliferative Neoplasms (2013) (12)
Deletions of the Transcription Factor Ikaros in Myeloproliferative Neoplasms at Transformation to Acute Myeloid Leukemia. (2009) (12)
Direct‐acting antivirals during or after immunochemotherapy in hepatitis C virus–positive diffuse large B‐cell lymphomas (2017) (12)
Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV) (2017) (12)
Erratum: A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence (2017) (12)
Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin’s lymphoma (2015) (12)
Mutational status of myeloproliferative neoplasms. (2010) (12)
Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients. (2019) (12)
ReTHINK: A randomized, double-blind, placebo-controlled, multicenter, phase 3 study of ruxolitinib in early myelofibrosis patients. (2016) (12)
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. (2018) (12)
Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation (12)
Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor Naïve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients (2020) (12)
Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma (2020) (11)
Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis. (2011) (11)
New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma (2016) (11)
Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden. (2016) (11)
Mechanisms of Adaptation to Ibrutinib in High Risk Chronic Lymphocytic Leukemia (2018) (10)
Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches. (2017) (10)
Blast phase of essential thrombocythemia: A single center study (2009) (10)
Health-related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT-II study. (2012) (10)
Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms. (2016) (10)
Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study (2020) (10)
Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation (2021) (10)
Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation (2010) (10)
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study. (2022) (9)
Deferasirox in the management of iron‐overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON‐M study) (2019) (9)
CELL THERAPY IN INFLAMMATORY BOWEL DISEASE. (2020) (9)
Pomalidomide Therapy in Anemic Patients with Myelofibrosis: Results from a Phase-2 Randomized Multicenter Study (2008) (9)
Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV) (2018) (9)
How to manage polycythemia vera (2012) (9)
Molecular and Clinical Features of the Myeloproliferative Neoplasm Associated with JAK2 Exon 12 Mutations: a European Multicenter Study (2009) (9)
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia (2005) (9)
A Dynamic Prognostic Model to Predict Survival in Primary Myelofibrosis: a Study of the International Working Group for Myeloproliferative Neoplasm Research and Treatment (IWG-MRT). (2009) (9)
Isolation and characterization of β-haemolytic-Streptococci from endometritis in mares. (2011) (9)
Immunochemotherapy with Rituximab, Vincristine and 5-Day Cyclophosphamide for Heavily Pretreated Follicular Lymphoma (2005) (9)
Insomnia, Quality Of Life and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG) (2013) (8)
Association of cytokine levels and reductions in spleen size in COMFORT-II, a phase III study comparing ruxolitinib to best available therapy (BAT). (2012) (8)
The Myleloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Derived Total Symptom Score (TSS): An International Trial of 1433 Patients with Myeloproliferative Neoplasms (MPNs), (2011) (8)
Validation of the "fitness criteria" for the treatment of older patients with acute myeloid leukemia: A multicenter study on a series of 699 patients by the Network Rete Ematologica Lombarda (REL). (2020) (8)
Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms (2011) (8)
Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm (MPN)-Associated Intermediate- or High-Risk Myelofibrosis (MF) Resistant or Intolerant to Ruxolitinib: An Updated Analysis of the Phase II JAKARTA2 Study (2019) (8)
RESPONSE 2: A phase 3b study evaluating the efficacy and safety of ruxolitinib in patients with hydroxyurea (HU)-resistant/intolerant polycythemia vera (PV) versus best available therapy (BAT). (2014) (8)
Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma (2017) (8)
Fedratinib Induces Spleen Responses and Reduces Symptom Burden as First-line or Salvage Therapy in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) and Low Platelet Counts (2019) (7)
Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders (2021) (7)
Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug. (2004) (7)
Validation of cytogenetic-based risk stratification in primary myelofibrosis. (2010) (7)
Bone Marrow Biopsy and Aspirate Evaluation in 90 Patients with Essential Thrombocythemia Treated with PEG Interferon alpha-2b. Preliminary Results. (2004) (7)
Bayesian models identify specific lymphoproliferative disorders associated with hepatitis C virus infection (2009) (7)
Developments in diagnosis and treatment of essential thrombocythemia (2019) (7)
Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios (2021) (7)
Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial (2021) (7)
The Effect of Transfusion Dependency and Secondary Iron Overload on Survival of Patients with Myelodysplastic Syndrome. (2005) (7)
Clinical Relevance of Clonal Hematopoiesis in the Oldest-Old Population (2020) (7)
Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis. (2021) (7)
Increased Plasma Levels of lncRNAs LINC01268, GAS5 and MALAT1 Correlate with Negative Prognostic Factors in Myelofibrosis (2021) (7)
A new acute myeloid leukemia case with STAT5B-RARA gene fusion due to 17q21.2 interstitial deletion (2017) (7)
Conventional therapeutic options have limited impact on MPN symptoms: Insights from a prospective analysis of the MPN-SAF TSS (2012) (7)
A phase 1b, dose-finding study of ruxolitinib plus panobinostat in patients with myelofibrosis. (2014) (7)
Involvement of MAF / SPP 1 axis in the development of bone marrow fi brosis in PMF patients (2017) (6)
MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis - JAK Inhibitor-Naïe or With Suboptimal Response to Ruxolitinib - Preliminary Data From the MANIFEST Study. (2022) (6)
Fedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): A reanalysis of the JAKARTA-2 study. (2019) (6)
Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide (2020) (6)
Defining disease modification in myelofibrosis in the era of targeted therapy (2022) (6)
The Myelofibrosis Symptom Burden (MF-SB): An International Phenotypic Cluster Analysis of 329 Patients (2012) (6)
HARMONY: An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis (MF) (2014) (6)
Standard care and investigational drugs in the treatment of myelofibrosis (2019) (6)
Sexuality Challenges, Intimacy, and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG) (2013) (6)
Impact of bone marrow fibrosis grade in post‐polycythemia vera and post‐essential thrombocythemia myelofibrosis: A study of the MYSEC group (2019) (6)
RBC-transfusion guidelines update. (2012) (6)
A New International Multicenter-Based Model to Predict Survival in Myelofibrosis Secondary to Polycythemia and Thrombocythemia: The Mysec Prognostic Model (MYSEC-PM) (2014) (6)
Health-Related Quality of Life and Symptoms in Myelofibrosis Patients Treated with Ruxolitinib Versus Best Available Therapy (2011) (6)
The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study (2021) (6)
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts (2022) (5)
Looking for familial nodular lymphocyte‐predominant Hodgkin lymphoma (2013) (5)
Ruxolitinib in polycythemia vera: Follow-up from the RESPONSE trial. (2015) (5)
PEG Intron Treatment in 90 Patients with Essential Thrombocythemia (ET) Final Report of a Phase II Study. (2005) (5)
Klebsiella pneumoniae infection in Italian rabbits (2001) (5)
Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial (2021) (5)
HLA typing and VH gene rearrangement analysis in a family with hairy cell leukaemia (2007) (5)
Risk of Second Cancer in Nongastric Marginal Zone B-Cell Lymphomas of Mucosa-Associated Lymphoid Tissue: A Population-Based Study from Northern Italy (2007) (5)
Long-Term Effect of Ruxolitinib (RUX) in Inadequately Controlled Polycythemia Vera (PV) without Splenomegaly: 5-Year Results from the Phase 3 Response-2 Study (2020) (5)
COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA) (2022) (5)
A JAK 2V 617 F activating mutation in addition to KIT and FLT 3 mutations is associated with clinical outcome in patients with t ( 8 ; 21 ) ( q 22 ; q 22 ) acute myeloid leukemia (2009) (5)
Disease anticipation in familial myeloproliferative neoplasms. Authors' reply (2008) (4)
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): An International Prospective Validation Trial In 402 Patients (2010) (4)
Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosis in JUMP, a Phase 3b, expanded‐access study (2021) (4)
Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study (2018) (4)
Symptomatic burden in myelofibrosis (MF): Prospective international assessment in 128 MF patients. (2011) (4)
Reductions in JAK2V617F allele burden with ruxolitinib treatment in COMFORT-II, a phase III study comparing the safety and efficacy of ruxolitinib to best available therapy (BAT). (2012) (4)
Platelet count predicts driver mutations’ co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis (2020) (4)
Clinical predictors of outcome in MPN. (2012) (4)
Bone Marrow Evaluation According to the PVSG and WHO Criteria in 90 Essential Thrombocythemia (ET) Patients Treated with PEG Interferon alpha-2b. Preliminary Results. (2005) (4)
The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis (2022) (4)
The future of research in hematology: Integration of conventional studies with real-world data and artificial intelligence. (2021) (4)
Role of the molecular staging and response in the management of follicular lymphoma patients (2006) (4)
Relationship Between Granulocyte JAK2 (V617F) Mutant Allele Burden and Risk of Progression to Myelofibrosis in Polycythemia Vera: a Prospective Study of 338 Patients. (2009) (4)
Symptom Burden and Health-Related Quality Of Life (HRQoL) In Patients With Myelofibrosis (MF) Treated With Fedratinib (SAR302503) In a Phase III Study (JAKARTA) (2013) (3)
Molecular Response Patterns in Hydroxyurea (HU)-Resistant or Intolerant Polycythemia Vera (PV) during Treatment with Idasanutlin: Results of an Open-Label, Single-Arm Phase 2 Study (2020) (3)
Symptom Severity and Clinical Variables of Polycythemia Vera Patients with Splenomegaly, Phlebotomy Requirements and/or Hydroxyurea Use : a Retrospective Evaluation of 1334 Patients (2014) (3)
Loss of Heterozygosity on Chromosome 9p24 Is the Most Frequent Chromosomal Aberration in Polycythemia Vera and Idiopathic Myelofibrosis. (2004) (3)
MIPSS70: Mutation-Enhanced Prognostic System for Transplant Age Patients with Primary Myelofibrosis (2017) (3)
Immunogenicity and clinical efficacy of anti‐SARS‐CoV‐2 vaccination in patients with hematological malignancies: Results of a prospective cohort study of 365 patients (2022) (3)
JAKARTA: A phase III, multicenter, randomized, double-blind, placebo-controlled, three-arm study of SAR302503 in patients with intermediate-2 or high-risk primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF with splenomegaly. (2012) (3)
A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2) (2021) (3)
In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent (2019) (3)
Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID‐19: The GIMEMA EMATO‐0321 study (2022) (3)
DIPSS-Plus: A Refined Dynamic International Prognostic Scoring System (DIPSS) for Primary Myelofibrosis That Incorporates Karyotype, Platelet Count and Transfusion Status (2010) (3)
Gender Differences and MPN Symptom Burden : An Analysis by the MPN Quality of Life International Study Group (MPN-QOL ISG) (2014) (3)
How I treat How I treat polycythemia (2012) (3)
Ruxolitinib for the Treatment of Inadequately Controlled Polycythemia Vera without Splenomegaly: 156-Week Follow-up from the Phase 3 Response-2 Study (2018) (3)
Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative (2019) (3)
Efficacy of a combination of idarubicin, etoposide and intermediate-dose cytosine arabinoside as salvage therapy in relapsing or resistant unfavorable lymphoma. (1998) (3)
Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to the WHO Criteria. A Basis for Clinical Decision-Making. (2004) (3)
Chromosomal Aberration Network In Myeloproliferative Neoplasms (2010) (3)
PS1465 SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS WITH MYELOFIBROSIS (MF) AND ANEMIA (HB <10 G/DL): RESULTS AT WEEK (WK) 24 OF THE REALISE TRIAL (2019) (3)
Towards a Better Understanding of Epidemiology, Survival and Treatment in Myeloproliferative Neoplasms: Results of the European Leukemianet Registry (ERNEST study) (2014) (3)
Thrombosis History and Relationship with Low Thrombocytosis, Leukocytosis, and Jak2 V617F Mutation In A Cohort of 977 Patients with Essential Thrombocythemia (ET): Preliminary Report of the Registro Italiano Trombocitemia(RIT) (2011) (3)
Chronic myeloproliferative neoplasms in the elderly. (2018) (3)
Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review. (2022) (2)
New and old prognostic factors in polycythemia vera (2009) (2)
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients (2022) (2)
HCV Infection in Nongastric Marginal Zone B-Cell Lymphoma of MALT. (2005) (2)
Secondary infections worsen the outcome of COVID‐19 in patients with hematological malignancies: A report from the ITA‐HEMA‐COV (2022) (2)
Antibody Response to COVID-19 Vaccination in Adults with Haematological Malignancies: A Systematic Review and Meta-Analysis (2021) (2)
Bortezomib-based therapy in non-transplant multiple myeloma patients: a retrospective cohort study from the FABIO project (2021) (2)
Loss of Heterozygosity of Chromosome 1p34 and High Mutant Allele Burden in Patients with Post-Essential Thrombocythemia Myelofibrosis Carrying Somatic Mutations of MPL (2008) (2)
The EHA Research Roadmap: Malignant Myeloid Diseases (2021) (2)
Research on some production and hygiene-sanitary aspects of laying hens raised in floor pens and in cages. (2004) (2)
Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm (2012) (2)
Clinical Benefit of Ruxolitinib Treatment after Crossover from Best Available Therapy in Patients with Polycythemia Vera: Analysis of the RESPONSE Trial (2014) (2)
A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses (2022) (2)
COVID-19 Infection in Vaccinated Adult Patients with Hematological Malignancies. Preliminary Results from Epicovideha (Epidemiology of COVID-19 infection in patients with hematological malignancies: A European Haematology Association Survey) (2021) (2)
SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates (2022) (2)
Management of patients with lymphoma and COVID‐19: Narrative review and evidence‐based practical recommendations (2022) (2)
A Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm: A Study from the AGIMM Group (2014) (2)
A final note about ibrutinib in relapsed or refractory CLL: Conclusive results from RESONATE sound definitely good! (2019) (2)
INCB018424, a Selective Inhibitor of JAK1 and JAK2, Downregulates the Expression of Leukocyte Alkaline Phosphatase (LAP) On Circulating Granulocytes in Patients with Polycythemia Vera and Essential Thrombocythemia. (2009) (2)
PS1458 RISK FACTORS AND OUTCOME OF ACUTE MYELOID LEUKEMIA SECONDARY TO POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT (2019) (2)
Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms (2022) (2)
A PROGNOSTIC MODEL to PREDICT SURVIVAL In WHO-DEFINED ESSENTIAL THROMBOCYTHEMIA: A STUDY by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) (2011) (2)
Myelofibrotic transformation in essential thrombocythemia. Author reply (2009) (2)
COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey (2022) (2)
P1051: A PHASE 2 STUDY OF IMG-7289 (BOMEDEMSTAT) IN PATIENTS WITH ADVANCED MYELOFIBROSIS (2022) (2)
Lack of efficacy of convalescent plasma in COVID‐19 patients with concomitant hematological malignancies: An Italian retrospective study (2022) (2)
Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study (2020) (2)
Changes in Quality of Life and Disease-Related Symptoms in Patients with Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results (2014) (2)
Survival of Allogeneic Stem Cell Transplantation Vs Conventional Therapies per DIPSS Stratification in Patients with Primary Myelofibrosis Younger Than 65 Years: A Retrospective Analysis on 673 Patients (2014) (2)
PRIMARY MYELOFIBROSIS, POST-ET AND POST-PV MYELOFIBROSIS HAVE DISTINCT CLINICAL PROFILES AND SYMPTOMATIC BURDENS : AN ANALYSIS BY THE MPN QUALITY OF LIFE INTERNATIONAL STUDY GROUP (MPN-QOL ISG) (2015) (2)
Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus–Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi (2022) (2)
A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study (2022) (2)
Classification of myeloproliferative neoplasms and prognostic factors. (2012) (2)
Bendamustine in Combination with Gemcitabine and Vinorelbine (BEGEV) Is an Effective Regimen for Heavily Pretreated, Relapsed/Refractory Hodgkin Lymphoma Patients: A Multicenter, Retrospective Real-World Study (2018) (2)
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study (2023) (2)
Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolitinib (RUX), Regardless of Reason for Discontinuing RUX (2019) (2)
MPN-149: Long-Term Safety of Momelotinib in JAK Inhibitor-Naïve and Previously JAK Inhibitor-Treated Intermediate-/High-Risk Myelofibrosis Patients (2020) (2)
Escalated dosing schedules of CC-486 for patients experiencing first acute myeloid leukemia (AML) relapse: Results from the phase III QUAZAR AML-001 maintenance trial. (2020) (2)
Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs) (2015) (2)
Stem cell mobilization after bendamustine in indolent lymphomas: a multicenter study on behalf of the Fondazione Italiana Linfomi (2020) (2)
PDGFRB disease: right diagnosis to prolong survival. (2014) (1)
Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden. (2016) (1)
Splenic Marginal Zone B-Cell Lymphoma: Clinical Clustering of Immunoglobulin Heavy Chain Repertoires. (2008) (1)
The Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Mediates Responses Suggestive of Disease Modification (2022) (1)
Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized, Placebo-Controlled, Phase III JAKARTA Study (2019) (1)
Anemia in myelofibrosis: current and emerging treatment options. (2022) (1)
INO-CD22: A Multi-Center, Real-Life Study on Inotuzumab-Ozogamicin Safety and Effectiveness in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (2021) (1)
Direct‐acting antivirals in hepatitis C virus‐positive mantle cell lymphomas (2020) (1)
Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT. (2022) (1)
P1041: IMPACT OF FEDRATINIB ON SPLEEN VOLUME AND MYELOFIBROSIS SYMPTOMS IN PATIENTS WITH SUBSTANTIAL SPLENOMEGALY: POST HOC ANALYSES FROM THE JAKARTA AND JAKARTA2 TRIALS (2022) (1)
The double significance of idelalisib immune-related toxicity (2021) (1)
Real-World Outcomes with Fedratinib Therapy in Patients Who Discontinued Ruxolitinib for Primary Myelofibrosis (2021) (1)
Analysis of three screening methods for the detection of calreticulin gene mutations (2020) (1)
and Treatment study of the International Working Group for Myelofibrosis Research New prognostic scoring system for primary myelofibrosis based on a (2013) (1)
Symptom Burden Profile in Myelofibrosis Patients with Thrombocytopenia: Lessons and Unmet Needs (2015) (1)
Primary leptomeningeal CNS lymphoma presenting as bilateral facial nerve palsy (2014) (1)
Clonal B-Cell Lymphocytosis with Mariginal-Zone Features: Comparison with Overt Splenic Marginal-Zone Lymphomas in 77 Patients from a Monocentric Series (2019) (1)
Several Somatic Mutations of JAK2 Exon 12 Are Found in Patients with a JAK2 (V617F)-Negative Myeloproliferative Disorder That Is Mainly Characterized by Erythrocytosis. (2007) (1)
Palpitations And Arrhythmia In 3649 High-Risk Patients With Essential Thrombocythemia : Results From The Prospective Long-Term Observational Exels Study (2016) (1)
High Resolution Array-CGH in Splenic Marginal Zone B-Cell Lymphoma: Correlation of Copy Number Imbalances with HCV Status and Prognostic Categories. (2007) (1)
Differential Expression of Genes Related to JAK-STAT Pathway Activation or Megakaryocyte Differentiation/Maturation in CD34+ Cells from Patients with Refractory Anemia with Ringed Sideroblasts and Thrombocytosis (RARS-T). (2007) (1)
Response to “Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions” by Heidel et al. (2018) (1)
Pre-Treatment with Bendamustine Does Not Affect Stem Cell Mobilization in Patients with Indolent Non-Hodgkin Lymphomas: A Multicenter Study on Behalf of the Fondazione Italiana Linfomi (2018) (1)
Demographics, Baseline Characteristics, and Disease Symptom Burden in RESPONSE-2: A Randomized, Phase 3 Study of Ruxolitinib in Polycythemia Vera Patients (pts) Who Are Resistant to or Intolerant of Hydroxyurea (HU) (2015) (1)
A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET) (2022) (1)
Granulocyte JAK2 (V617F) Mutation Status in Myeloid Neoplasms with Ringed Sideroblasts. (2006) (1)
Risk Factors for Thrombosis Among 1,545 Patients with Polycythemia Vera: An International Study. (2012) (1)
Post-Polycythemia and Post-Thrombocythemia Myelofibrosis Have Distinctive Clinical Phenotypes: An International Multicenter Study on 718 Patients (2014) (1)
P1058: REAL-WORLD OUTCOMES WITH FEDRATINIB THERAPY IN PATIENTS WITH PRIMARY MYELOFIBROSIS POST-RUXOLITINIB DISCONTINUATION (2022) (1)
Ibrutinib dose intensity in high‐risk chronic lymphocytic leukemia (2022) (1)
S197: NAVITOCLAX PLUS RUXOLITINIB IN JAK INHIBITOR-NAÏVE PATIENTS WITH MYELOFIBROSIS: PRELIMINARY SAFETY AND EFFICACY IN A MULTICENTER, OPEN-LABEL PHASE 2 STUDY (2022) (1)
Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study (2021) (1)
PS1459 FEDRATINIB IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASM (MPN)-ASSOCIATED MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX): A REANALYSIS OF THE PHASE 2 JAKARTA-2 STUDY (2019) (1)
Pomalidomide Therapy in Myelofibrosis: 2-Year Follow-up of a Randomized Phase 2 Study. (2009) (1)
Differences in Clinical and Molecular Characteristics and Outcome in Prefibrotic and Overt Primary Myelofibrosis According to 2016 WHO Criteria. a Study on 639 Patients of the Agimm Group (2016) (1)
Hydroxyurea Treatment In 1075 Patients with Essential Thrombocythemia and Occurrence of Extra-Hematological Adverse Events: A Preliminary Report of the Registro Italiano Trombocitemia (RIT) (2010) (1)
Myelofibrosis. (2022) (1)
Therapy of polycythemia vera: is it time to change? (2017) (1)
Real-World Clinical Outcomes of Patients with Myelofibrosis Treated with Ruxolitinib: Evidence from a Multinational Medical Record Review (2020) (1)
Transfusion Independence Response As a Potential Surrogate for Overall Survival in Jaki-Experienced Patients with Myelofibrosis from Momentum (2022) (1)
JAK2V617F Molecular Response to Ruxolitinib in Patients with PV and ET Is Associated with Lower Risk of Progression to Secondary Myelofibrosis (2022) (1)
DIRECT‐ACTING ANTIVIRALS DURING OR AFTER IMMUNO‐CHEMOTHERAPY IN HEPATITIS C VIRUS‐ASSOCIATED DIFFUSE LARGE B‐CELL LYMPHOMAS (2017) (1)
Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide (2018) (1)
Impact Of Splenomegaly On Mpn Symptoms And Association With Clinical Features : An Analysis By The Mpn Quality Of Life International Study Group (2016) (1)
MPN-332: Clinical Benefit of Pelabresib (Cpi-0610) in Combination with Ruxolitinib in JAK Inhibitor Treatment-Naïve Myelofibrosis Patients: Interim Efficacy Subgroup Analysis from Arm 3 of the MANIFEST Phase 2 Study (2021) (1)
Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI) (2021) (1)
Prediction of Overall Survival in 520 Patients with Primary Myelofibrosis: Outcome Update of the Dynamic International Prognostic Scoring System (DIPSS) Patient Cohort (2012) (1)
Balancing efficacy and safety of JAK inhibitors in myelofibrosis. (2014) (1)
Molecular characterization of Philadelphia-negative myeloproliferative neoplasms (2010) (0)
A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis (2022) (0)
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score (2022) (0)
Development of an MF patient reported outcome (PRO) tool for FDA qualification: Comprehensive literature search and physician cognitive debriefing results (2016) (0)
Adherence to Treatment in Myelofibrosis Patients: Preliminary Results from Italian Romei Observational Study (2019) (0)
Identification of SETBP1 As an Epigenetic Hub Protein That Induces the Transcription of a Network of Development-Related Genes (2017) (0)
Essential Thrombocythemia (ET) and Polycythemia Vera (PV) Symptom Burden: Phenotypic Cluster Analysis Among an International Sample of 1,141 ET and PV Patients (2012) (0)
Haploidentical cellular therapy in elderly patients with acute myeloid leukemia: Description of (2013) (0)
Spleen and Symptom Responses with Fedratinib (FEDR) in Patients with Myelofibrosis (MF) and Substantial Splenomegaly (2021) (0)
Symptomatic profiles of 1334 polycythemia vera patients: implications of inadequately controlled disease (2016) (0)
Stereotyped Patterns of HCDR3 Sequences in Splenic Marginal Zone B-Cell Lymphoma (SMZL): SMZL-Biased Subsets Are Associated with a Worse Outcome. (2009) (0)
S281: PRIOR EXPOSURE TO IMMUNOSUPPRESSIVE AGENTS AND COMORBIDITIES ARE ASSOCIATED WITH WORSE OUTCOMES OF SARS-COV2 INFECTION IN PH-NEG CHRONIC MYELOPROLIFERATIVE NEOPLASMS: RESULTS OF EPICOVIDEHA SURVEY (2022) (0)
Spliceosome Mutations Are Common in MPN-Associated Myelofibrosis with RBC-Transfusion-Dependence and Correlate with Response to Pomalidomide (2018) (0)
Germline RBBP6 mutations in familial myeloproliferative neoplasm (2016) (0)
Prognostication in myelofibrosis (2015) (0)
Baseline Mutational Status of Patients with Myelofibrosis and Anemia in the Realise Trial and Impact on Outcome (2019) (0)
A new prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment Short title: Prognostic scoring system of primary myelofibrosis (2008) (0)
R27Low toxicity profile of the combination of bendamustine plus rituximab in elderly frail patients with newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (2015) (0)
An International Multicenter Project on Secondary Myelofibrosis (2016) (0)
Polycythemia Vera: Is It Time to Rethink Treatment? (2021) (0)
Bone Marrow Biopsy Revision According to WHO Criteria in 272 Patients of the Registro Italiano Trombocitemia (RIT): Preliminary Report On Clinical and Histopathological Implications. (2009) (0)
S244: EFFECT OF ANTI-SPIKE NEUTRALIZING MONOCLONAL ANTIBODIES ON COVID-19 PROGRESSION AND TIME TO VIRAL CLEARANCE IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AND SARS-COV-2 INFECTION: THE GIMEMA EXPERIENCE (2022) (0)
PF655 PROGNOSTIC RELEVANCE OF THE GENE EXPRESSION SIGNATURE IN PRIMARY AND SECONDARY MYELOFIBROSIS (2019) (0)
Relationship between peripheral blood and bone marrow CD34-positive cell counts in patients with Ph-negative chronic myeloproliferative disorder and its potential clinical implications. (2005) (0)
Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group (2014) (0)
thrombocythemia carrying the JAK2 (617V>F) mutation Increased risk of pregnancy complications in patients with essential (2013) (0)
Patients with Unexplained Thrombosis Require a Prompt Investigation to Search a Chronic Myeloproliferative Neoplasm (MPN), Even If Platelet Count Is <600x109/L. Analysis on 129 Patients from Registro Italiano Trombocitemie (RIT) (2015) (0)
Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes (2022) (0)
myeloproliferative disorders and constitutive mobilization of CD34+ cells into peripheral blood in Relation between JAK2 (V617F) mutation status, granulocyte activation, (2013) (0)
Erratum: Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders (British Journal of Haematology (2004) 126 (650-656)) (2005) (0)
IBRUTINIB TOLERABILITY AND OUTCOME IN PATIENTS WITH HIGH‐RISK CHRONIC LYMPHOCYTIC LEUKEMIA (2021) (0)
Comparison of the Myleloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Across Nine Linguistic Translations Among an International Sample of 1,851 Myeloproliferative Neoplasm (MPN) Patients. (2012) (0)
Low Toxicity Profile of the Combination of Bendamustine Plus Rituximab (BR) in Elderly FRAIL Patients with Newly Diagnosed DLBCL (2014) (0)
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project (2018) (0)
Characteristics of High-Risk Polycythemia Vera Patients with Suboptimal Response to First-Line Therapy Who Switched to Ruxolitinib Vs Those Who Did Not Switch: Findings from PV-Switch, a Multinational, Retrospective Chart Review Study (2021) (0)
Clinical Outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib (2022) (0)
Evidence of Polyclonal Hematopoiesis in a Large Proportion of Patients with Low-Risk Myelodysplastic Syndrome. (2004) (0)
Sequential Evaluation of the Proportion of Granulocyte JAK2 (V617F) Mutant Alleles in Chronic Myeloproliferative Disorders. (2006) (0)
Impact of Direct-Acting Antivirals on the Outcome of HIV/HCV Coinfected Patients with Non-Hodgkin Lymphomas in the Modern Anti-Retroviral Therapy Era: A Retrospective Multicenter Study of 74 Cases (2021) (0)
Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI) (2022) (0)
Understanding New WHO Classification of MPNs (2017) (0)
Myeloproliferative Neoplasms Research and Treatment ) formyelofibrosis : a study by the IWG-MRT ( International Working Group A dynamic prognostic model to predict survival in primary (2010) (0)
Cytoreductive Therapeutic Approach in the Essential Thrombocythemia (ET) Patients of the Registro Italiano Trombocitemia (RIT): Preliminary Data (2008) (0)
Impact of Disease Burden in Myelofibrosis Patients: A Sub Analysis from Italian Romei Observational Study (2019) (0)
Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinib (2022) (0)
Clinical Phenotype and Genotype Correlations with Time to Progression into Post Polycythemia Vera and Post Essential Thrombocythemia Myelofibrosis (2017) (0)
Characterization of Chromosome 20q Deletions In Myeloproliferative Neoplasms Using Microarray Karyotyping and Next-Generation Sequencing (2010) (0)
Acquired Thrombotic Thrombocytopenic Purpura After ChAdOx1 nCoV-19 Vaccine: A Case Report (2022) (0)
CLL-358: Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated by Epigenetic Plasticity of Residual Disease and Bypass Signaling via the MAPK Pathway (2021) (0)
Low Risk IPSS/DIPSS Primary Myelofibrosis: Identification of Patients with Higher Risk of Progression (2014) (0)
Gene Expression Profiling Defines a Set of New Molecular Markers for Sporadic and Familial Myeloproliferative Disorders. (2004) (0)
Molecular Characterization of Diffuse Large B-Cell Lymphoma Associated to Hepatitis C Virus Infection (2021) (0)
ADAPTATION OF CHRONIC LYMPHOCYTIC LEUKEMIA TO IBRUTINIB IS MEDIATED BY EPIGENETIC PLASTICITY OF RESIDUAL DISEASE AND BY‐PASS SIGNALING VIA MAPK PATHWAY (2021) (0)
Efficacy of Ruxolitinib in Chronic Eosinophilic Leukemia Associated with t(8;9)(p22;p24) and PCM1-JAK2 Fusion Gene. (2012) (0)
Thrombosis History and Relationship With Low Thrombocytosis, Leukocytosis, and Other Characteristics At Diagnosis In 977 Essential Thrombocythemia Patients A Multivariate Analysis Of The Registro Italiano Trombocitemie (RIT) (2013) (0)
P987: A DIFFERENT BALANCE IN OXIDATIVE STRESS RESPONSE IN CALR AND JAK2 MUTATED MYELOFIBROSIS PATIENTS CORRELATES WITH CLINICAL OUTCOME (2022) (0)
Risk Stratification in PMF (2012) (0)
Real-World Management of Myelofibrosis with Ruxolitinib: Initial Analysis of an Italian Observational Study (ROMEI) (2018) (0)
Dermatitis-cellulitis in broiler chickens. Bacteriological and pathological findings [slaughterhouse - Umbria] (1997) (0)
P995: MYELOID NEOPLASMS-ASSOCIATED GENE VARIANTS IN 639 PATIENTS WITH POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT (2022) (0)
Relationship between JAK2 V617F Mutation Status and Constitutive Mobilization of CD34-Positive Cells into Peripheral Blood in Patients with Chronic Myeloproliferative Disorder. (2005) (0)
Agents of zoonosis in wild city pigeons and in meat pigeons. (2000) (0)
SARS‐CoV‐2 infection and vaccination in patients with hairy‐cell leukaemia (2022) (0)
A Population-Based Study on Survival of Higher Risks Myelofibrosis Patients Treated with Ruxolitinib in the Italian Lombardy Region (2022) (0)
MPN-095: Fedratinib Elicits Spleen Volume or Symptom Responses in a Majority of Patients with Intermediate- or High-Risk Myelofibrosis (MF) Treated for 6 Cycles: Results from the JAKARTA and JAKARTA2 Studies (2020) (0)
Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (2019) (0)
editor: Germline RBBP6 mutations in familial myeloproliferative neoplasms (2016) (0)
P1292: MOLECULAR CHARACTERIZATION OF DIFFUSE LARGE B-CELL LYMPHOMA ASSOCIATED TO HEPATITIS C VIRUS INFECTION (2022) (0)
Chronic myeloproliferative diseases: Polycythemia, thrombocythemia, myelofibrosis - Preface (2006) (0)
Anagrelide of its Use in the Management of Essential Thrombocythaemia (2006) (0)
P1003: PERIPHERAL BLOOD CYTOTOXIC T CELLS SHOW EARLY EXHAUSTED FEATURES IN MYELOFIBROSIS PATIENTS (2022) (0)
Platelet Count Predicts Co-occurrence of Driver Mutations in Essential Thrombocythemia and Myelofibrosis with a Low JAK2 Allele Burden (2019) (0)
Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients (2018) (0)
Verify: A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera (2022) (0)
Agents of zoonosis in pigeons of city and in meat pigeons [Marche - Umbria] (2000) (0)
Mutational Status of TET2, JAK2, and MPL in Refractory Anemia with Ringed Sideroblasts Associated with Marked Thrombocytosis. (2009) (0)
Relationship between JAK2 V617F Mutation Status, Granulocyte CD177 mRNA Expression and CD177 Soluble Protein Level in Patients with Polycythemia Vera. (2005) (0)
Clinical Features and Prognostic Assessment of Nodal Marginal Zone B-Cell Lymphoma, a Rare Disease with Follicular-Like Behaviour. (2006) (0)
Hygienic aspects of meat pigeon slaughtering (2000) (0)
Consideration of Symptom Burden Based Treatment in PV and ET Patients: An Analysis By MPN International Quality of Life Study Group (2016) (0)
exon 12 mutations JAK2 associated with Molecular and clinical features of the myeloproliferative neoplasm (2013) (0)
A Sex-Informed Approach to Improve Prognostication and Personalized Decision-Making Process in Myelodysplastic Syndromes. a European Study of 11.878 Patients (2020) (0)
Validation and further potentialities of the novel AWM score for progression risk stratification in patients with asymptomatic Waldenström macroglobulinemia (2019) (0)
Peripheral Blood Cytotoxic T Cells from Myelofibrosis Patients Show Early Exhausted Features Targetable By CTLA-4 Inhibition (2022) (0)
An outbreak of Moraxella spp. infection in meat rabbits (1998) (0)
Management of Post ET/PV MF: Different from Primary MF (2017) (0)
Calreticulin Mutation Does Not Modify the International Prognostic Score for Predicting the Risk of Thrombosis Among 1,150 Patients with Essential Thrombocythemia (2014) (0)
SARS‐CoV‐2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID‐19 cohort (2022) (0)
Immunoglobulin Heavy Chain (IGH) Gene Rearrangement In Waldenström Macroglobulinemia and Other Monoclonal IgM Disorders (2010) (0)
sideroblasts associated with marked thrombocytosis Molecular and clinical features of refractory anemia with ringed (2013) (0)
Interim 18f-PDGPET for Aggressive Non-Hodgking's Lymphoma: A Systematic Review and Meta-Analysis (2011) (0)
Efficacy of an infectious bursal disease (IBD) vaccine administered in ovo. (2000) (0)
Investigations on the chemical, physical and microbiological characters of water samples from farms breeding rabbits, pigs and cattle and of hygiene and health aspects. (2002) (0)
myeloproliferative disorders Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative (2013) (0)
Unmet Needs for Symptom Control in Essential Thrombocythemia with Front Line Therapy (2015) (0)
PS1462 SECOND PRIMARY MALIGNANCIES IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB: REAL WORLD EVIDENCE FROM 215 CONSECUTIVELY TREATED PATIENTS IN LOMBARDY (2019) (0)
Risk Factors for Thrombosis in WHO-Defined Early/Prefibrotic Myelofibrosis: An International Study of 264 Patients, (2011) (0)
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis. (2023) (0)
Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry (2023) (0)
Prospective Validation of the Italian Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF: Italian) In 186 MPN Patients (2010) (0)
Clinical and Biological Features in Patients with Ph-Negative Chronic Myeloproliferative Neoplasm Showing Different Molecular Pattern. Comparative Study in 596 Patients of the Registro Italiano Trombocitemie (RIT) (2015) (0)
Sensitivity and Specificity of Laboratory Parameters to Detect Early/Prefibrotic Myelofibrosis in 857 Patients with Essential Thrombocythemia. A Diagnostic Algorithm (2011) (0)
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub (2018) (0)
P1607: EPICOVIDEHA KIDS: A READY TO USE PLATFORM FOR EPIDEMIOLOGICAL STUDIES IN PEDIATRIC HEMATOLOGICAL PATIENTS WITH COVID-19 (2022) (0)
Acute Myeloid Leukemia with Isocitrate Dehydrogenases (IDH) 1 and 2 Mutations. a Real-World Study from the European IDH Research Group (2020) (0)
Review for "Impaired Virus‐Specific T Cell Responses in Patients with Myeloproliferative Neoplasms Treated with Ruxolitinib" (2020) (0)
Gene expression pro ﬁ le correlates with molecular and clinical features in patients with myelo ﬁ brosis (2021) (0)
P1000: INCREASED PLASMA LEVELS OF LNCRNAS ARE POTENTIAL PROGNOSTIC BIOMARKERS IN MYELOFIBROSIS (2022) (0)
Transfusion Need at Diagnosis or Its Development During the First Year of Diagnosis in Primary Myelofibrosis: Effect On Survival and Correlation with JAK2 and TET2 Mutational Status. (2009) (0)
(IPSET-thrombosis) essential thrombocythemia - thrombosis in World Health Organization Development and validation of an International Prognostic Score of (2013) (0)
Myelofibrosis: Prognostication and cytoreductive treatment (2014) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Francesco Passamonti?

Francesco Passamonti is affiliated with the following schools:

University of Insubria
University of Milan
University of Pavia
University of Padua
University of Barcelona
University of Bologna